ALNYLAM PHARMACEUTICALS ($ALNY) posted quarterly earnings results on Thursday, May 1st. The company reported earnings of -$0.01 per share, beating estimates of -$1.05 by $1.04. The company also reported revenue of $594,190,000, missing estimates of $597,538,072 by $-3,348,072.
You can see Quiver Quantitative's $ALNY stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ALNYLAM PHARMACEUTICALS Insider Trading Activity
ALNYLAM PHARMACEUTICALS insiders have traded $ALNY stock on the open market 188 times in the past 6 months. Of those trades, 0 have been purchases and 188 have been sales.
Here’s a breakdown of recent trading of $ALNY stock by insiders over the last 6 months:
- PUSHKAL GARG (CMO & EVP Dev & Med Affairs) has made 0 purchases and 55 sales selling 72,393 shares for an estimated $20,350,640.
- YVONNE GREENSTREET (Chief Executive Officer) has made 0 purchases and 32 sales selling 13,209 shares for an estimated $3,265,437.
- PHILLIP A SHARP sold 11,250 shares for an estimated $3,093,750
- DAVID E I PYOTT sold 7,440 shares for an estimated $2,224,560
- KEVIN JOSEPH FITZGERALD (CSO & EVP, Head of Research) has made 0 purchases and 48 sales selling 8,354 shares for an estimated $2,075,576.
- JEFFREY V. POULTON (EVP, Chief Financial Officer) has made 0 purchases and 32 sales selling 4,709 shares for an estimated $1,169,424.
- TOLGA TANGULER (EVP, Chief Commercial Officer) has made 0 purchases and 19 sales selling 2,453 shares for an estimated $607,489.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ALNYLAM PHARMACEUTICALS Hedge Fund Activity
We have seen 310 institutional investors add shares of ALNYLAM PHARMACEUTICALS stock to their portfolio, and 253 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL INTERNATIONAL INVESTORS removed 2,552,261 shares (-64.3%) from their portfolio in Q4 2024, for an estimated $600,572,535
- CAPITAL RESEARCH GLOBAL INVESTORS added 1,724,610 shares (+32.9%) to their portfolio in Q4 2024, for an estimated $405,817,979
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 1,245,195 shares (+39.7%) to their portfolio in Q4 2024, for an estimated $293,006,835
- FMR LLC removed 1,186,369 shares (-8.1%) from their portfolio in Q4 2024, for an estimated $279,164,489
- BAILLIE GIFFORD & CO removed 846,741 shares (-17.3%) from their portfolio in Q4 2024, for an estimated $199,246,624
- WELLINGTON MANAGEMENT GROUP LLP removed 756,724 shares (-15.3%) from their portfolio in Q4 2024, for an estimated $178,064,724
- QUBE RESEARCH & TECHNOLOGIES LTD added 333,098 shares (+218.9%) to their portfolio in Q4 2024, for an estimated $78,381,290
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ALNYLAM PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $ALNY in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Scotiabank issued a "Outperform" rating on 03/21/2025
- Bernstein issued a "Outperform" rating on 01/07/2025
To track analyst ratings and price targets for ALNYLAM PHARMACEUTICALS, check out Quiver Quantitative's $ALNY forecast page.
ALNYLAM PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $ALNY recently. We have seen 2 analysts offer price targets for $ALNY in the last 6 months, with a median target of $324.0.
Here are some recent targets:
- An analyst from Scotiabank set a target price of $338.0 on 03/21/2025
- William Pickering from Bernstein set a target price of $310.0 on 01/07/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
